Karyopharm Therapeutics (KPTI) Capital Expenditures (2013 - 2024)

Karyopharm Therapeutics has reported Capital Expenditures for 11 years, with the latest figure at -$53000.0 in Q4 2024.

• For the quarter ending Q4 2024, Capital Expenditures changed N/A year-over-year to -$53000.0; the trailing twelve-month figure through Sep 2025 stood at -$53000.0 (down 127.18% YoY), and the FY2024 full-year result was $142000.0, changed N/A from the prior year.
• Capital Expenditures for Q4 2024 stood at -$53000.0, down from $195000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $207000.0 in Q4 2021, with the low at -$53000.0 in Q4 2024.
• Historically, Capital Expenditures has averaged $68555.6 across 4 years, with a median of $39000.0 in 2022.
• Annual changes were most pronounced in 2020 — Capital Expenditures plunged 79.59% — and 2022, when it soared 680.0%.
• Karyopharm Therapeutics' Capital Expenditures stood at $119000.0 in 2020, then soared by 73.95% to $207000.0 in 2021, then slumped by 81.16% to $39000.0 in 2022, then sank by 235.9% to -$53000.0 in 2024.
• The last three Capital Expenditures figures came in at -$53000.0 (Q4 2024), $195000.0 (Q1 2024), and $39000.0 (Q3 2022), per Business Quant data.